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1. Introduction
   Drug resistance is one of the problem in cancer 
therapy, especially in breast cancer. Breast cancer is 
the first ranked cases of cancer in women worldwide. In 
developing countries, breast cancer is the second leading 
cause of death after cervical cancer. In Indonesia, breast 
cancer patients as much as 12.10%, are the second largest 
number after cervical cancer (19.18%). The high mortality 
rate indicates the treatment with chemotherapy has not 
overcome the cancer. Strategies and the development of 
breast cancer treatment should be pursued. Problems in 
the chemotherapy of breast cancer becomes larger, since 
the emergence of breast cancer resistance to chemotherapy 
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Objective: To evaluate of hesperidin to overcome resistance of doxorubicin in MCF-7 resistant 
doxorubicin cells (MCF-7/Dox) in cytotoxicity apoptosis and P-glycoprotein (Pgp) expression in 
combination with doxorubicin.
Methods: The cytotoxic properties, 50% inhibition concentration (IC50) and its combination with 
doxorubicin in MCF-7 cell lines resistant to doxorubicin (MCF-7/Dox) cells were determined 
using MTT assay. Apoptosis induction was examined by double staining assay using ethidium 
bromide-acridine orange. Immunocytochemistry assay was performed to determine the level and 
localization of Pgp.
Results: Single treatment of hesperidin showed cytotoxic activity on MCF-7/Dox cells with 
IC50 value of 11 µmol/L. Thus, combination treatment from hesperidin and doxorubicin showed 
addictive and antagonist effect (CI>1.0). Hesperidin did not increase the apoptotic induction, but 
decreased the Pgp expressions level when combined with doxorubicin in low concentration.
Conclusions: Hesperidin has cytotoxic effect on MCF-7/Dox cells with IC50 of 11 µmol/
L. Hesperidin did not increased the apoptotic induction combined with doxorubicin. Co-
chemotherapy application of doxorubicin and hesperidin on MCF-7/Dox cells showed synergism 
effect through inhibition of Pgp expression.
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agents[1].
   Breast cancer cell resistance to chemotherapeutic agents 
is caused by various factors, but it is predominantly due 
to increased Akt activity and expression of multi-drug 
resistance 1 (MDR1) gene, the gene encoding P-glycoprotein 
(Pgp) after administration of doxorubicin[2,3]. Because 
of these problems, the development of breast cancer 
chemotherapy directed to the combination of doxorubicin 
with other compounds (co-chemotherapy) that can increase 
the effectiveness of doxorubicin[4]. One of the proteins that 
regulate the proliferation and survival genes is NF-êB[5].
   Hesperidin, a citrus flavonoid showed strong toxic effect in 
Caco-2, CEM/ADR5000 and CCRF-CEM cancer cell lines with 
IC50, 195, 230 and 95 µmol/L, respectively[6]. Hesperidin also 
showed antiproliferative effect in MCF-7 cells transfected 
with green fluoresens protein (GFP)/alpha-tubulin (MCF-7-
GFP-Tubulin)[7]. It is also reported that hesperidin protective 
effect in Benzo(a)pirene induced testicular toxicity paradigm 
and repaired the function of lactate dehydrogenase, 
superoxide dismutase, and glutathione-S-transferase 
enzyme[8]. Previous study has reported that hesperidin 
could induce apoptosis in human colon cancer cells through 
Caspase-3 (CASP3) activation. Hesperidin down-regulated 
the protein expression of pro-CASP3, and upregulated the 
level of active CASP3[9]. 
   This study was conducted to determine the effect 
of hesperidin performed on MCF-7, MCF-7/Dox cells. 
Cytotoxicity effect of hesperidin, apoptosis induction and Pgp 
expression observations made on single and combination 
with doxorubicin. The results of this study is expected to be 
used as a reference for further research in order to explore 
hesperidin as an alternative to co-chemotherapy agent in 
breast cancer therapy.
2. Materials and methods
2.1. Chemical and reagent
   H e s p e r i d i n ,  d i m e t h y l  s u l f o x i d e  ( D M S O ) , 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-
bromide (MTT) were purchased from Sigma Chemical 
Co., St Louis, MO, USA;  rabbit anti-Pgp and horseradish 
peroxidase-conjugated goat antimouse or anti-rabbit 
secondary antibodies, CA; Dulbecco’s modified Eagle 
medium (DMEM) high glucose medium and fetal bovine serum 
from Gibco, Grand Island, NY; 96-well plates from Iwaki.
2.2. Cell culture and cytotoxicity assay
   MCF-7 and MCF-7/Dox human breast cancer cell line was a 
generous gift from the laboratory of Prof. M Kawaichi (NAIST, 
Japan). Cells maintained in DMEM high glucose medium 
supplemented with 10% fetal bovine serum, 1% penicillin-
streptomycin at 37 °C in 5% CO2 incubator. To study the 
cytotoxic effect of hesperidin, confluent cell cultures were 
trypsinized and seeded in 96-well plates at a density of 1伊
10
4 cells per well in growth medium. After 24 h, cells were 
treated with various concentrations of hesperidin (dissolved 
in DMSO as a stock solution). The DMSO concentration in the 
final cell treatment solutions was less than 0.1%. After 24 h of 
treatments, cells were washed with Phosphate Buffer Solution 
(PBS) and 100 µL of MTT solution (0.5 mg/mL in DMEM medium) 
was added. Four hours later, the precipitated formazan was 
dissolved in 100 µL of sodium dodecyl sulfonate stopper 
reagent. Cell viability was determined by measuring the 
absorbance at 595 nm using microplate reader (Biorad). In 
this study, the drug concentration required to inhibit cell 
growth by 50% (IC50) was determined from a plot of percent 
cell viability from control untreated cells versus treated 
cells.
2.3. Apoptotic assay
   Apoptosis was detected using acrydine orange-etidium 
bromide staining (acridine orange/ethidium bromide double 
staining). MCF-7/Dox cells (5伊104 cells/well) were seeded on 
cover slips in 24-well plates until 50%-60% confluent. Cells 
were incubated with hesperidin alone, doxorubicin alone 
and their combination for 24 h. Culture medium was removed 
and cells were washed with PBS. Coverslips were placed 
into object-glass and added with 10 µL 1X working solution 
acrydine orange (Sigma)-etidium bromide (Sigma), observed 
using fluoroscence microscopy (Zeiss MC 80). Apoptotic cells 
which had lost their membrane integrity appeared orange 
and showed morphological features of apoptosis. Cells were 
identified as apoptotic on the basis of specific morphological 
criteria, including condensation and fragmentation of 
chromatin, and formation of apoptotic bodies.
2.4. Immunocytochemistry assay
   MCF-7 and MCF-7/Dox cells were plated at 5伊104 cells/
well and cultured in 24-wells plate at cover slip until 80% 
confluent. At time 0, medium was replaced by fresh complete 
medium with hesperidin 3.5 µmol/L and doxorubicin 230 
nmol/L and placed in CO2 5% incubator at 37 °C for 18 h. 
Then, cells were harvested and were washed with PBS and 
fixed with cold methanol for 10 min at freezer -40 °C. Cells 
washed and blocked in hydrogen peroxide blocking solution 
for 10 min at room temperature. After that, cells washed with 
PBS and incubated with prediluted blocking serum for 10 
min at room temperature. Cells were stained for 1 h at room 
temperature with primary Pgp antibody. After washing three 
times in PBS, secondary antibody were applied for 15-30 
min, 1:2 in PBS and added 5% AB serum then washed with 
PBS three times. The slide was incubated with streptavidin-
biotin complex for 15 min, 1:2 in PBS and added 5% AB serum 
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and washed three times in PBS. Slides were incubated in 
3,3 diaminobenzidin solution for 3-8 min and washed with 
aquadest. Cells were counterstained for 3-4 min with Mayer-
Haematoksilin. After incubation, cover slip washed with 
aquadest and then immersed with xylol and alcohol. Protein 
expression was assessed under light microscope. Positive 
expression will give a dark brown colour in cell membrane 
and cells with no expression will give purple colour.
3. Results 
3.1. Effect of hesperidin and its combination with doxorubicin 
on cell viability
   Cell viability assay was done to determine the IC50 of 
hesperidin alone and its combination with doxorubicinon 
MCF-7/Dox cells. All of these compounds showed growth 
inhibitory effect in dose dependent manner. Hesperidin and 
doxorubicin had the IC50 values of 11 µmol/L (Figure 1) and 
700 nmol/L, respectively. The combination of hesperidin 
and doxorubicin increased the viability cells higher than 
hesperidin alone (Figure 2). This result showed that the 
combination resulted antagonist effect. 
3.2. Effect of hesperidin and doxorubicin on apoptosis induction
   All of hesperidin or doxorubicin alone were capable of 
inducing apoptosis at inhibitory concentration, but when they 
were combined does not showed  apoptotic induction (Figure 
3). The green fluorescence indicates the viable cells while the 
orange-red fluorescence indicates the death cells. Apoptotic 
cells show the occurrence of chromatin condensation and the 
orange-red apoptotic bodies. Combination of hesperidin and 
doxorubicin appeared does not showed apoptotic induction.
3.3. Effect of hesperidin and doxorubicin toward Pgp 
expression on MCF-7/Dox cells line
   To confirm the mechanism of hesperidin and its 
combination with doxorubicin induced apoptosis, this 
research observed the effect of hesperidin, doxorubicin 
and their  combinat ion on Pgp expression using 
immunocytochemistry method. Interestingly, the expression 
of Pgp on the hesperidin and doxorubicin-treated cells 
was decreased compare to the control cells. The decreasing 
level of Pgp expression on the combination treated cells was 
higher than on the hesperidin or doxorubicin single treated 
cells (Figure 4). Moreover, the increasing level of Pgp 
expression on the both single compared with combination 
treated cells showed significantly different, but still 
higher than the control cells. These data showed that the 
combination more potent to reduce the Pgp expression on 
the MCF-7/Dox cells than single treatment.
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Figure 1. The effect of hesperidin on viability of MCF-7/Dox cells.
Tests were carried out by incubating 5伊103 MCF-7/Dox cells in 96-well plates 
for 24 h to adapt, then treated hesperidin concentrations of 1-100 µmol/L, 
then incubated again for 24 h. Profiles of cell viability expressed mean±SD 
of 3 experiments (A). Obvious morphological changes and cell populations in 
the treatment of hesperidin concentrations of 10 (C), 50 (D), and 100 µmol/L (E) 
compared with controls (B). Black arrow indicates a normal living cells, whereas 
white arrows indicate the cell morphology changes. Cell morphology observations 
conducted with an inverted microscope with a magnification of 100伊. IC50 of 11 
µmol/L obtained from the linear regression calculation of cell viability vs log 
concentrations with P<0.05. 
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Figure 2. Combination effect of hesperidin-doksorubisin on viability of 
MCF-7/Dox cells. 
Tests were carried out by incubating 5伊103 MCF-7/Dox cells in 96-well plates 
for 24 h to adapt, then given a single treatment and combination of hesperidin 
0.5, 1.25, 2.5 and 3.5 µmol/L, and doxorubicin 35, 87.5, 175 and 233 nmol/L, and 
then incubated again for 24 h. Profiles of cell viability expressed mean±SD of 3 
experiments. Hesperidin is not able to enhance doxorubicin effects in reducing 
cell viability (A). Changes in cell morphology seen in the treatment of hesperidin 
least 3.5 µmol/L (C), treatment of 233 nmol/L doxorubicin (D), and the treatment of 
hesperidin combination of 3.5 µmol/L and 233 nµmol/L doxorubicin (E) compared 
with controls (B). Black arrow indicates a normal living cells, whereas white 
arrows indicate the cell morphology changes. Cell morphology observations 
conducted with an inverted microscope with a magnification of 100伊. Doxorubicin 
combination treatment of cell viability 3.5 µmol/L and 233 nmol/L hesperidin did 
not differ significantly to 233 nmol/L doxorubicin single (P<0.05).
Rifki Febriansah et al./Asian Pac J Trop Biomed 2014; 4(3): 228-233 231
Figure 3. Apoptosis induction of hesperidin, doxorubicin and its combination 
on MCF-7/Dox cells in 24-well plates . 
A: all cells seen alive in the control; B: incidence of apoptosis treated with 230 
nmol/L doxorubicin; C: incidence of apoptosis treated with 3.5 µmol/L hesperidin; 
D: Incidence of apoptosis treated with combination of 3.5 µmol/L hesperidin 
and 230 nmol/L doxorubicin not increased significantly; Arrows: the place where 
the incidence of apoptotic cells seen any fragmentation of the cell nucleus. 
Observations made under a fluorescent microscope with a magnification of 100伊.
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Figure 4. The effect of hesperidin, doxorubicin and its combination on Pgp 
expression on MCF-7/Dox cells. 
Tests were carried out by incubating 5伊104 MCF-7/Dox cells on coverslips in 24 
wells plates for 24 h to adapt, then were subjected to 230 nmol/L doxorubicin, 
hesperidin 3.5 µmol/L and a combination of both. Tues incubated for 18 h and 
Pgp staining done as mentioned in the research procedure. Control cells without 
primary anti-Pgp antibody did not showed the brown color on the cell membrane 
(A). Control cells with antibodies showed expression of Pgp viewed from the cell 
membrane of brown color (B). In the doxorubicin group showed expression of 
the increasingly intense brown color on the cell membrane (C). Hesperidin and 
combination with doxorubicin (D and E) showed a decrease in the intensity of 
brown color when compared with doxorubicin single treatment group.
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4. Discussion
   The aim of  this research was to investigate the biological 
activity of hesperidin to overcome cancer cell resistance 
because of doxorubicin chemotherapy drugs. MTT assay 
showed that hesperidin able to increase of MCF-7/Dox 
cells sensitivity to doxorubicin with IC50 value of 11 µmol/
L. It was lower than the MCF-7 (ori) of 200 µmol/L[10]. The 
combination of hesperidin with doxorubicin was interesting 
in overcoming resistance through its action in suppressing 
the Pgp expression.
   One of the mechanisms of cancer cell resistance to 
anticancer agents associated with MDR1 gene expression 
and the over-expression of Pgp protein, which could pumps 
the drugs out of cells. The MCF-7/Dox cells resistant to 
doxorubicin is experiencing over-expression of Pgp. Pgp 
encoded by the MDR1 gene and protein products transported 
through endosom with early transport to the plasma 
membrane. The MCF-7/Dox that overexpression of Pgp has 
been successfully made in this study with the method of 
induction by low concentration of doxorubicin.
   Hesperidin was able to increase the sensitivity of cells 
with decreased the IC50 value to MCF-7/Dox of 11 µmol/
L compared to MCF-7 cells. These results were consistent 
with several studies which showed that polyphenols such 
as flavonols quersetin increase the sensitivity of cells that 
are resistant to daunorubicin[11]. Several other flavonoids 
like silymarin were able to reverse the function of Pgp[12]. 
Flavonoid compounds also able to modulate Pgp expression 
so that the amount of intracellular doxorubicin increase and 
provide a greater cytotoxic effect.
   Doxorubicin is a chemotherapy agent that is widely 
used in the treatment of various epithelial cancers. In the 
previous study showed that doxorubicin has a high potential 
as anticancer agents, Fitriasari et al. (2010) in MCF-7 
cells and Junedi et al. (2010) in T47D cells showed that 
doxorubicin could inhibit cell growth with IC50 values were 
460 nmol/L and 15 nmol/L, respectively[13-14]. Mechanism of 
doxorubicin is formed intercalation with DNA. It will directly 
affect the transcription and replication. Doxorubicin is able 
to form a tripartite complex with topoisomerase II and DNA. 
   From the research, it resulted that doxorubicin has IC50 
value of 700 nmol/L in MCF-7/Dox cells. On the combination 
of hesperidin with doxorubicin, it did not show a strong 
cytotoxic effect and combination index had high value 
(additive to antagonist effect). This is probably due to 
flavonoids such as hesperidin which are antioxidants will 
inhibit the cytotoxic activity of doxorubicin. Research about 
hesperidin as an antioxidant has been widely reported 
previously[15]. Mechanism of hesperidin as antioxidant was 
to inhibit the peroxidation of linoleic acid induced by Fe2+ 
and autooxidation in membranes cerebral and inhibits the 
production of reactive oxygen species including hydroxyl 
radicals and nitric oxide (NO)[16]. In contrast with the 
anticancer activity of doxorubicin, one of the mechanisms 
of doxorubicin in inhibiting the progression of cancer is to 
stimulate the production of reactive oxygen species and NO 
that would undermine the stability of DNA and eventually 
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will cause death of cancer cells. The combination of 
hesperidin with doxorubicin in this study proved to be 
potent and synergistic in inhibiting cancer cell growth. 
This is probably due to a mechanism that is opposite 
from the second agent. This is an interesting research 
findings, in which a natural compound in combination 
with chemotherapeutic agents did not always produce a 
synergistic effect. To explore the mechanism of action of 
this combination, it is necessary to observe the mechanism 
of cell death and see that the modulation of protein 
expression plays a role against the resistance of cancer 
cells, namely Pgp.
   The results of apoptosis by double staining method in the 
treatment of hesperidin (3.5 µmol/L) showed that only a few 
occurrence of the phenomenon of apoptosis. Similar results 
are also shown in the treatment of hesperidin combination 
with doxorubicin, while a single doxorubicin could increase 
the occurrence of apoptosis. This is consistent with the 
results of combination between hesperidin and doxorubicin 
at low concentrations showed no cytotoxic effects, even to 
additive and antagonistic. This is in line with research of 
Sakata et al. (2003) which showed that hesperidin can reduce 
the occurrence of cell apoptosis through its ability to reduce 
the overproduction of NO as a result of an inhibitory effect 
on the expression and activity of inducible nitric oxide 
synthase[17,18].
   From the results of Pgp observation was known that the 
combination of hesperidin with doxorubicin to inhibit 
the expression of Pgp in MCF-7/Dox cells. This was shown 
by a decrease in the intensity of brown color on the cell 
membrane compared to doxorubicin single tratment. This is 
consistent with previous studies that flavonoids including 
hesperidin can be located as a substrate of Pgp on 
adenosine triphosphate binding site, so that the expression 
of Pgp will be decreased[19-23]. So the prospect of hesperidin 
has developed further as Pgp expression-suppressing 
agents.
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Comments 
Background
   Drug resistance is one of the problems in cancer therapy, 
especially in breast cancer. Strategies and the development 
of breast cancer treatment should be pursued. Problems 
in the chemotherapy of breast cancer become larger, since 
the emergence of breast cancer resistance to chemotherapy 
agents.
  
Research frontiers
   Hesperidin has antiproliferative effect on MCF-7 cells. 
This study aimed to determine the effect of hesperidin 
on MCF-7 and MCF-7/Dox cells. The study demonstrated 
cytotoxicity of hesperidin, apoptosis induction and Pgp 
expression, when given singly and combination with 
doxorubicin. The results will be basic research in order to 
explore hesperidin as an alternative to co-chemotherapy 
agent in breast cancer therapy.
Related reports
   Hesperidin showed strong toxic effect in Caco-2, CEM/
ADR5000 and CCRF-CEM cancer cell lines with dengan IC50, 
195, 230 and 95 µmol/L, respectively. Hesperidin protects 
benzo(a)pirene-induced testicular toxicity by repairing the 
function of lactate dehydrogenase, superoxide dismutase, 
dan glutathione-S-transferase enzymes. Also, hesperidin is 
able to induce apoptosis in human colon cancer cell lines 
by CASP3 activation.
Innovations and breakthroughs
   Hesperidin possesses a variety of biological properties, 
including cancer chemoprevention. In this in vitro study, 
the authors demonstrated that hesperidin could be used for 
lowering breast cancer resistance to chemotherapy agents.
  
Applications
   It is well-known that resistance to chemotherapy is one 
of the major problems to treat breast cancer. This study 
suggests that hesperidin can be used for reducing resistance 
to breast cancer chemotherapy, by single treatment or in 
combination with anti-cancer agents.   
Peer review
   This is an interesting and valuable research work. The 
authors demonstrated that hesperidin has cytotoxic effect 
on MCF-7/Dox cells with IC50 of 11 µmol/L. Hesperidin 
did not increased the apoptotic induction combined with 
doxorubicin. Co-chemotherapy application of doxorubicin 
and hesperidin on MCF-7/Dox cells showed synergism effect 
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through inhibition of Pgp expression.
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